A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases

2011

New Test for Prostate Cancer Using Autoantibodies and PSA

Sample size: 252 publication 10 minutes Evidence: moderate

Author Information

Author(s): Xie Chong, Kim Hyun J, Haw Jonathan G, Kalbasi Anusha, Gardner Brian K, Li Gang, Rao Jianyu, Chia David, Liong Monty, Punzalan Rubio R, Marks Leonard S, Pantuck Allan J, de la Taille Alexandre, Wang Guomin, Mukouyama Hideki, Zeng Gang

Primary Institution: Department of Urology, Zhongshan Hospital of Fudan University

Hypothesis

Can a novel multiplex assay combining autoantibodies and PSA improve the classification of prostate cancer from non-malignant cases?

Conclusion

The A+PSA assay may help in diagnosing and predicting prostate cancer more effectively than PSA alone.

Supporting Evidence

The A+PSA index improved sensitivity and specificity for prostate cancer diagnosis compared to PSA alone.
The study involved a large sample size of prostate cancer and benign prostatic hyperplasia patients.
Statistical analysis showed significant differences in autoantibody levels between cancer and non-cancer patients.
The A+PSA assay reduced the false positive rate of PSA tests.

Takeaway

Researchers created a new test that combines two types of markers to better tell if someone has prostate cancer or not.

Methodology

The study used a multiplex assay to measure autoantibodies and total PSA in serum samples from prostate cancer and benign prostatic hyperplasia patients.